Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV‐Challenged Nonhuman Primates (Adv. Therap. 3/2021)

In article number 2000163, Alessandro Grattoni and colleagues perform the first ever HIV preventive efficacy study using a subcutaneous drug delivery implant. The implant uses a nanofluidic membrane to sustainably deliver tenofovir alafenamide fumarate (TAF), a HIV antiretroviral, without pumps or a...

Full description

Saved in:
Bibliographic Details
Published in:Advanced therapeutics 2021-03, Vol.4 (3), p.n/a
Main Authors: Pons‐Faudoa, Fernanda P., Sizovs, Antons, Shelton, Kathryn A., Momin, Zoha, Niles, Jean A., Bushman, Lane R., Xu, Jiaqiong, Chua, Corrine Ying Xuan, Nichols, Joan E., Demaria, Sandra, Ittmann, Michael M., Hawkins, Trevor, Rooney, James F., Marzinke, Mark A., Kimata, Jason T., Anderson, Peter L., Nehete, Pramod N., Arduino, Roberto C., Ferrari, Mauro, Sastry, K. Jagannadha, Grattoni, Alessandro
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In article number 2000163, Alessandro Grattoni and colleagues perform the first ever HIV preventive efficacy study using a subcutaneous drug delivery implant. The implant uses a nanofluidic membrane to sustainably deliver tenofovir alafenamide fumarate (TAF), a HIV antiretroviral, without pumps or actuation. Long‐term sustained TAF release, controlled through physical and electrostatic confinement in the nanochannels of the membrane, obviates daily oral dosing to provide protection from HIV infection in nonhuman primates.
ISSN:2366-3987
2366-3987
DOI:10.1002/adtp.202170005